Pradaxa Lawsuits on the Rise: Next Trial to Begin Sept. 2018
Pradaxa Lawsuits on the Rise: Next Trial to Begin Sept. 2018
Introduction
Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. is an anticoagulant prescribed to prevent blood clots and reduce the risk of stroke. The drug which was approved by FDA in 2010, allegedly caused serious injuries like internal bleeding in several patients. Some reports indicate Pradaxa use led to gastrointestinal bleeding, heart attack, stroke, brain hemorrhage, kidney bleeding, and death.
In 2014, the drug maker agreed to settle more than 4,100 lawsuits for $650 million. More than 2,400 lawsuits, filed after that settlement, are pending in the state court against Boehringer Ingelheim. The first two trials held in March 2018 and May 2018 concluded verdicts in favor of the defendants. The next set of trials are slated to begin in September 2018 and February 2019.
In December 2017, Judge Herndon recommended termination of Pradaxa multidistrict litigation (MDL 2385; In Re: Pradaxa [Dabigatran Etexilate] Products Liability Litigation), which was formed in 2012 in the Southern District of Illinois.
Comments
Latest News
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…
Purdue, Sacklers Agree to New $7.4B Opioid Settlement
Categories: Opioids
All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.
This deal addresses allegations that the company’s aggressive and…
Oregon to Get $66M in Sackler Opioid Settlement
Categories: Opioids
Oregon will gain $66 million as part of a nationwide settlement with the Sackler family and Purdue Pharma, the makers of OxyContin. The funds will be used to expand and…